Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer
Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer
复制标题
DOI：
10.1111/j.1365-2559.2009.03378.x
复制
发表时间：
2009-09-01
期刊：
影响因子：
6.4
通讯作者：
Gu, Jin
中科院分区：
文献类型：
--
作者：
Wang, Qi;Chen, Zhi-Guo;Gu, Jin
目的：CD133抗原已被确定为结直肠癌组织中可能的干细胞标记物。根据癌症干细胞假说，CD133+细胞决定了肿瘤的长期生长，因此被怀疑影响临床结果。目的是探讨CD133在直肠癌患者术前放疗和治愈性切除后的预后价值。方法与结果：采用免疫组化方法，对73例不同分期的直肠癌患者进行了肿瘤细胞CD133干细胞抗原的表达分析。评估CD133表达及其他临床病理因素的预后价值。在多变量生存分析中，CD133+细胞的比例是不良无病生存和总生存的显著预后因素（P < 0.05），与ypTNM分期、肿瘤分化或淋巴血管侵袭无关。结论：CD133干细胞抗原表达与直肠癌患者生存相关，支持目前的癌症干细胞假说。
Aims:The CD133 antigen has been identified as a putative stem cell marker in colorectal cancer tissues. According to the cancer stem cell hypothesis, CD133+ cells determine long-term tumour growth and are therefore suspected of influencing clinical outcome. The aim was to investigate the prognostic value of CD133 expression in rectal cancer patients after preoperative radiation and curative resection.Methods and results:The expression of the CD133 stem cell antigen in a series of 73 patients with rectal cancer of various ypTNM stages was analysed by immunohistochemistry on formalin-fixed paraffin-embedded sections. The prognostic value of CD133 expression and other clinicopathological factors was evaluated. On multivariate survival analysis, the proportion of CD133+ cells was a significant (P < 0.05) prognostic factor for adverse disease-free survival and overall survival independent of ypTNM stage, tumour differentiation or lymphovascular invasion.Conclusions:CD133 stem cell antigen expression correlates with patient survival in rectal cancer, lending support to the current cancer stem cell hypothesis.